Literature DB >> 9701463

Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients.

H Wada1, N Sakuragawa, H Shiku.   

Abstract

The changes in various hemostatic parameters were examined within a period from 7 days before the onset of disseminated intravascular coagulation (DIC) in 114 patients (i.e. in their pre-DIC state). The changes in prothrombin time (PT) ratio and fibrinogen levels were not significant before the onset of DIC. Plasma fibrinogen and fibrin degradation products (FDP) levels before the onset of DIC were high, but these changes were already significant in 110 non-DIC patients examined. Plasma thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer and soluble fibrin monomer (SFM) levels were high before the onset of DIC. In the 110 leukemic DIC patients, the plasma SFM levels were significantly increased 5 days before, the plasma TAT levels were significantly increased 3 days before, and the D-dimer levels were significantly increased 1 day before the onset of DIC. The plasma tissue factor and plasminogen activator inhibitor-I levels were not significantly changed before the onset of DIC. The PT ratio, fibrinogen, FDP, platelet count, antithrombin, D-dimer, and PPIC levels at 7 days before the onset of DIC were not significantly different from the corresponding values in the non-DIC group, although the hemostatic molecular markers SFM, D-dimer, and TAT are useful for the diagnosis of pre-DIC. Plasma thrombomodulin levels were significantly increased in these patients who died, and plasma antithrombin and protein C activities markedly reduced in the patients who died. The outcome of the diseases underlying DIC is related to vascular endothelial cell injuries.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701463     DOI: 10.1055/s-2007-995857

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

1.  Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2012-01-21       Impact factor: 2.490

2.  Negative predictive value of D-dimer for diagnosis of venous thromboembolism.

Authors:  Hideki Nomura; Hideo Wada; Toshiro Mizuno; Naoyuki Katayama; Yasunori Abe; Maki Noda; Kaname Nakatani; Takeshi Matsumoto; Satoshi Ota; Norikazu Yamada; Akihiro Sudo; Atsumasa Uchida; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-02-19       Impact factor: 2.490

3.  Cut-off values of D-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery.

Authors:  Akihiro Sudo; Hideo Wada; Tsutomu Nobori; Norikazu Yamada; Masaaki Ito; Rui Niimi; Masahiro Hasegawa; Koji Suzuki; Atsumasa Uchida
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

4.  Significance of plasma D-dimer in relation to the severity of atherosclerosis among patients evaluated by non-invasive indices of cardio-ankle vascular index and carotid intima-media thickness.

Authors:  Shigeru Hayashi
Journal:  Int J Hematol       Date:  2010-06-18       Impact factor: 2.490

5.  Elevated levels of soluble fibrin in patients with venous thromboembolism.

Authors:  Akihiro Tsuji; Hideo Wada; Takeshi Matsumoto; Yasunori Abe; Satoshi Ota; Norikazu Yamada; Takashi Sugiyama; Akihiro Sudo; Katsuya Onishi; Kaname Nakatani; Atsumasa Uchida; Masaaki Ito; Koji Suzuki; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

6.  Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy.

Authors:  M Y Lee; C C Verni; B A Herbig; S L Diamond
Journal:  J Thromb Haemost       Date:  2017-10-27       Impact factor: 5.824

7.  Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema.

Authors:  Masahiko Sugimoto; Yasuko Wakamatsu; Ryohei Miyata; Takayasu Nunome; Yumiho Tenma; Hisashi Matsubara; Mineo Kondo; Hideo Wada; Kaname Nakatani
Journal:  Sci Rep       Date:  2019-08-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.